• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者的特征、管理和骨肉瘤的结局:国家癌症数据库的结局分析。

Characteristics, Management, and Outcomes of Patients With Osteosarcoma: An Analysis of Outcomes From the National Cancer Database.

机构信息

From the Department of Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, CT (Dr. Ottesen, Shultz, Dr. Munger, Sibindi, Yurter, Dr. Varthi, and Dr. Grauer), and the Harvard Combined Orthopedic Residency Program, Harvard Medical School, Boston, MA (Dr. Ottesen).

出版信息

J Am Acad Orthop Surg Glob Res Rev. 2022 Feb 22;6(2):e22.00009. doi: 10.5435/JAAOSGlobal-D-22-00009.

DOI:10.5435/JAAOSGlobal-D-22-00009
PMID:35192571
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8865506/
Abstract

INTRODUCTION

Previous studies about osteosarcoma patient characteristics, management, and outcomes have limited patient numbers, combine varied tumor types, and/or are older studies.

METHODS

Patients with osteosarcoma from the 2004 to 2015 National Cancer Database data sets were separated into axial, appendicular, and other. Demographic and treatment data as well as 1-, 5-, and 10-year survival were determined for each group. A multivariate Cox analysis of patient variables with the likelihood of death was performed, and the Kaplan Meier survival curves were generated.

RESULTS

Four thousand four hundred thirty patients with osteosarcoma (3,435 appendicular, 810 axial, and 185 other) showed survival at 1-year, 5-year, and 10-year and was highest among the appendicular cohort (91.17%, 64.43%, and 58.58%, respectively). No change in survival was seen over the periods studied. The likelihood of death was greater with increasing age category, distant metastases, and treatment with radiation alone but less with appendicular primary site, treatment with surgery alone, or surgery plus chemotherapy.

DISCUSSION

Despite advances in tumor management, surgical excision remains the best predictor of survival for osteosarcomas. No difference was observed in patient survival from 2004 to 2015 and, as would be expected, distant metastases were a poor prognostic sign, as was increasing age, male sex, and axial location.

摘要

简介

以前关于骨肉瘤患者特征、治疗和预后的研究,患者数量有限,肿瘤类型多样,或研究较陈旧。

方法

从 2004 年至 2015 年国家癌症数据库的数据集中,将患有骨肉瘤的患者分为轴性、附肢性和其他类型。对每个组别的人口统计学和治疗数据以及 1 年、5 年和 10 年的生存率进行了确定。对具有死亡可能性的患者变量进行了多变量 Cox 分析,并生成了 Kaplan-Meier 生存曲线。

结果

4430 例骨肉瘤患者(3435 例附肢性,810 例轴性,185 例其他)的 1 年、5 年和 10 年生存率最高,附肢性肿瘤患者的生存率最高(分别为 91.17%、64.43%和 58.58%)。在所研究的时间段内,生存率没有变化。随着年龄、远处转移和单纯放疗的增加,死亡的可能性增加,但随着附肢性原发性肿瘤、单纯手术治疗或手术加化疗的增加,死亡的可能性降低。

讨论

尽管肿瘤治疗取得了进展,但外科切除仍然是骨肉瘤生存的最佳预测因素。2004 年至 2015 年期间,患者的生存率没有差异,而且正如预期的那样,远处转移是一个不良预后的标志,年龄、性别、轴性位置也是不良预后的标志。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276f/8865506/ae522d0b1fff/jagrr-6-e22.00009-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276f/8865506/208e72f58e27/jagrr-6-e22.00009-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276f/8865506/cf698b16d1df/jagrr-6-e22.00009-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276f/8865506/ae522d0b1fff/jagrr-6-e22.00009-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276f/8865506/208e72f58e27/jagrr-6-e22.00009-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276f/8865506/cf698b16d1df/jagrr-6-e22.00009-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276f/8865506/ae522d0b1fff/jagrr-6-e22.00009-g003.jpg

相似文献

1
Characteristics, Management, and Outcomes of Patients With Osteosarcoma: An Analysis of Outcomes From the National Cancer Database.患者的特征、管理和骨肉瘤的结局:国家癌症数据库的结局分析。
J Am Acad Orthop Surg Glob Res Rev. 2022 Feb 22;6(2):e22.00009. doi: 10.5435/JAAOSGlobal-D-22-00009.
2
Chondrosarcoma patient characteristics, management, and outcomes based on over 5,000 cases from the National Cancer Database (NCDB).基于国家癌症数据库(NCDB)超过 5000 例病例的软骨肉瘤患者特征、治疗和结局。
PLoS One. 2022 Jul 28;17(7):e0268215. doi: 10.1371/journal.pone.0268215. eCollection 2022.
3
Survival and prognostic factors at time of diagnosis in high-grade appendicular osteosarcoma: a 21 year single institution evaluation from east Denmark.在丹麦东部的一个单一机构进行了 21 年的研究,评估了高级肢端骨肉瘤诊断时的生存和预后因素。
Acta Oncol. 2018 Mar;57(3):420-425. doi: 10.1080/0284186X.2017.1351620. Epub 2017 Jul 25.
4
Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database.间叶性软骨肉瘤的生存率因年龄和肿瘤位置而异:基于监测、流行病学和最终结果(SEER)数据库的生存分析
Clin Orthop Relat Res. 2017 Mar;475(3):799-805. doi: 10.1007/s11999-016-4779-2.
5
Is Microscopic Vascular Invasion in Tumor Specimens Associated with Worse Prognosis in Patients with High-grade Localized Osteosarcoma?肿瘤标本中微血管侵犯是否与高级别局限性骨肉瘤患者的预后较差有关?
Clin Orthop Relat Res. 2020 Jun;478(6):1190-1198. doi: 10.1097/CORR.0000000000001079.
6
Cutaneous and subcutaneous metastasis of appendicular osteosarcoma in dogs: 20 cases.犬附肢骨肉瘤皮肤和皮下转移:20 例。
J Vet Intern Med. 2019 Sep;33(5):2200-2208. doi: 10.1111/jvim.15557. Epub 2019 Jul 11.
7
The extremity localized classic osteosarcomas have better survival than the axial non-classics.局限性经典型骨外骨肉瘤的存活率高于轴外非经典型。
World J Surg Oncol. 2018 Feb 23;16(1):39. doi: 10.1186/s12957-018-1344-3.
8
[Survival analysis of 104 cases of osteosarcoma with lung metastases].104例骨肉瘤肺转移患者的生存分析
Zhonghua Zhong Liu Za Zhi. 2017 Apr 23;39(4):263-268. doi: 10.3760/cma.j.issn.0253-3766.2017.04.005.
9
Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan.日本青少年和青年成人骨肉瘤患者的描述性流行病学及预后情况
BMC Musculoskelet Disord. 2018 Aug 18;19(1):297. doi: 10.1186/s12891-018-2217-1.
10
Is Surgical Resection of the Primary Site Associated with an Improved Overall Survival for Patients with Primary Malignant Bone Tumors Who Have Metastatic Disease at Presentation?对于初诊时即发生转移的原发性骨恶性肿瘤患者,外科切除原发灶是否能提高总生存率?
Clin Orthop Relat Res. 2020 Oct;478(10):2284-2295. doi: 10.1097/CORR.0000000000001361.

引用本文的文献

1
Autophagy Protease ATG4D Facilitates Proliferation and Malignancy of Osteosarcoma Cells.自噬蛋白酶ATG4D促进骨肉瘤细胞的增殖和恶性发展。
FASEB J. 2025 Sep 15;39(17):e70990. doi: 10.1096/fj.202501321RR.
2
Enhancing doxorubicin sensitivity in osteosarcoma via iRGD-modified biomimetic nanoparticles targeting MCAM m6A modification.通过靶向MCAM m6A修饰的iRGD修饰仿生纳米颗粒增强骨肉瘤对阿霉素的敏感性
J Transl Med. 2025 Jul 17;23(1):804. doi: 10.1186/s12967-025-06735-5.
3
Prognostic Factors in Newly Diagnosed High-Grade Osteosarcoma-A Systematic Review.

本文引用的文献

1
Adult Primary Bone Sarcoma and Time to Treatment Initiation: An Analysis of the National Cancer Database.成人原发性骨肉瘤与开始治疗的时间:国家癌症数据库分析
Sarcoma. 2018 Nov 11;2018:1728302. doi: 10.1155/2018/1728302. eCollection 2018.
2
Computer Navigation in Orthopaedic Tumour Surgery.计算机导航在骨科肿瘤手术中的应用。
Adv Exp Med Biol. 2018;1093:315-326. doi: 10.1007/978-981-13-1396-7_24.
3
Understanding osteosarcomas.了解骨肉瘤。
新诊断的高级别骨肉瘤的预后因素——一项系统综述
Cancer Med. 2025 Jul;14(14):e71044. doi: 10.1002/cam4.71044.
4
Comparison of overall survival of adult and pediatric osteosarcoma patients using the national cancer database.利用国家癌症数据库比较成人和儿童骨肉瘤患者的总生存率。
BMC Cancer. 2025 Feb 18;25(1):290. doi: 10.1186/s12885-025-13496-3.
5
Osteosarcoma and Ewing Sarcoma of Bone: An Italian Mono-Institutional Epidemiological Study.骨肉瘤和骨尤文肉瘤:一项意大利单中心流行病学研究。
Diagnostics (Basel). 2025 Jan 30;15(3):328. doi: 10.3390/diagnostics15030328.
6
Demographic and Treatment Analysis of Periosteal Osteosarcoma.骨膜骨肉瘤的人口统计学和治疗分析
Cancer Rep (Hoboken). 2024 Dec;7(12):e70086. doi: 10.1002/cnr2.70086.
7
IRF5 suppresses metastasis through the regulation of tumor-derived extracellular vesicles and pre-metastatic niche formation.IRF5 通过调节肿瘤来源的细胞外囊泡和转移前生态位形成来抑制转移。
Sci Rep. 2024 Jul 5;14(1):15557. doi: 10.1038/s41598-024-66168-w.
8
Extent of Surgery and Survival of Osteosarcoma: A Retrospective Population-Based Study.骨肉瘤的手术范围与生存率:一项基于人群的回顾性研究。
Cureus. 2024 Mar 12;16(3):e56030. doi: 10.7759/cureus.56030. eCollection 2024 Mar.
9
Osteosarcoma in Pediatric and Adult Populations: Are Adults Just Big Kids?儿童和成人人群中的骨肉瘤:成人只是大孩子吗?
Cancers (Basel). 2023 Oct 19;15(20):5044. doi: 10.3390/cancers15205044.
10
Analysis of prognostic factors and histopathological response to neoadjuvant chemotherapy in osteosarcoma.骨肉瘤新辅助化疗的预后因素及组织病理学反应分析。
Jt Dis Relat Surg. 2023;34(1):196-206. doi: 10.52312/jdrs.2023.902. Epub 2023 Jan 14.
JAAPA. 2018 Aug;31(8):15-19. doi: 10.1097/01.JAA.0000541477.24116.8d.
4
Osteosarcoma: a comprehensive review.骨肉瘤:一篇综述
SICOT J. 2018;4:12. doi: 10.1051/sicotj/2017028. Epub 2018 Apr 9.
5
Practical Guide to Surgical Data Sets: National Cancer Database (NCDB).《手术数据集实用指南:国家癌症数据库(NCDB)》
JAMA Surg. 2018 Sep 1;153(9):850-851. doi: 10.1001/jamasurg.2018.0492.
6
The extremity localized classic osteosarcomas have better survival than the axial non-classics.局限性经典型骨外骨肉瘤的存活率高于轴外非经典型。
World J Surg Oncol. 2018 Feb 23;16(1):39. doi: 10.1186/s12957-018-1344-3.
7
Team Approach: Osteosarcoma of the Distal Part of the Femur in Adolescents.团队协作:青少年股骨远端骨肉瘤
JBJS Rev. 2017 Dec;5(12):e5. doi: 10.2106/JBJS.RVW.17.00030.
8
Current and future therapeutic approaches for osteosarcoma.骨肉瘤的当前及未来治疗方法
Expert Rev Anticancer Ther. 2018 Jan;18(1):39-50. doi: 10.1080/14737140.2018.1413939. Epub 2017 Dec 14.
9
[Classical osteosarcoma in children and adolescent].[儿童和青少年的经典骨肉瘤]
Arkh Patol. 2015 Sep-Oct;77(5):68-74. doi: 10.17116/patol201577568-74.
10
Future directions in the treatment of osteosarcoma.骨肉瘤治疗的未来方向。
Curr Opin Pediatr. 2016 Feb;28(1):26-33. doi: 10.1097/MOP.0000000000000298.